Back

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants

Leier, H. C.; Bates, T. A.; Lyski, Z. L.; McBride, S. K.; Lee, D. X.; Coulter, F. J.; Goodman, J. R.; Lu, Z.; Curlin, M. E.; Messer, W. B.; Tafesse, F. G.

2021-04-29 infectious diseases
10.1101/2021.04.25.21256049 medRxiv
Show abstract

We compared the serum neutralizing antibody titers before and after two doses of the BNT162b2 COVID-19 vaccine in ten individuals who recovered from SARS-CoV-2 infection prior to vaccination to 20 individuals with no history of infection, against clinical isolates of B.1.1.7, B.1.351, P.1, and the original SARS-CoV-2 virus. Vaccination boosted pre-existing levels of anti-SARS-CoV-2 spike antibodies 10-fold in previously infected individuals, but not to levels significantly higher than those of uninfected vaccinees. However, neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees against every variant tested: 5.2-fold against B.1.1.7, 6.5-fold against B.1.351, 4.3-fold against P.1, and 3.4-fold against original SARS-CoV-2. Our study indicates that a first-generation COVID-19 vaccine provides broad protection from SARS-CoV-2variants in individuals with previous infection.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Medicine
○ 125 papers in training set
Top 0.1%
18.5%
Similar papers in this journal
2
New England Journal of Medicine
● 52 papers in training set
Top 0.1%
12.9%
Similar papers in this journal
3
Nature
○ 645 papers in training set
Top 2%
7.9%
Similar papers in this journal
4
Nature Communications
○ 5641 papers in training set
Top 23%
6.7%
Similar papers in this journal
5
npj Vaccines
○ 67 papers in training set
Top 0.2%
4.8%
Similar papers in this journal
50% of probability mass above
6
Clinical Infectious Diseases
◐ 235 papers in training set
Top 0.8%
4.0%
7
Med
○ 39 papers in training set
Top 0.1%
3.5%
8
Cell Reports Medicine
○ 153 papers in training set
Top 1%
2.7%
9
The Lancet Microbe
○ 44 papers in training set
Top 0.2%
2.6%
10
The Lancet Infectious Diseases
○ 73 papers in training set
Top 0.4%
2.4%
11
Cell Reports
○ 1498 papers in training set
Top 16%
2.1%
12
Science Translational Medicine
● 127 papers in training set
Top 1%
2.1%
13
Science
● 477 papers in training set
Top 5%
1.9%
14
Immunity
○ 67 papers in training set
Top 0.9%
1.9%
15
Cell Host & Microbe
126 papers in training set
Top 1%
1.7%
16
eBioMedicine
○ 183 papers in training set
Top 3%
1.7%
17
mBio
● 833 papers in training set
Top 8%
1.7%
18
Nature Immunology
○ 79 papers in training set
Top 1%
1.7%
19
Science Immunology
● 88 papers in training set
Top 2%
1.3%
20
The Journal of Infectious Diseases
◐ 202 papers in training set
Top 3%
1.1%
21
Nature Microbiology
○ 155 papers in training set
Top 3%
1.1%
22
Cell
○ 431 papers in training set
Top 9%
1.0%
23
iScience
○ 1154 papers in training set
Top 41%
0.6%
24
Microbiology Spectrum
● 469 papers in training set
Top 11%
0.6%
25
PLOS Medicine
● 110 papers in training set
Top 4%
0.6%
26
Science Advances
● 1243 papers in training set
Top 33%
0.6%
27
Cell Discovery
○ 57 papers in training set
Top 1%
0.6%
28
Scientific Reports
○ 3612 papers in training set
Top 77%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.